SecBot SecBot
SECBOTREPLAY Home › Report › TCRT

TCRT · S-3 for 382M share resale

Alaunos Therapeutics, Inc. · S-3 filed Nov 12, 2026 at 19:49 ET

At the news

BEARISHIMPACT 6/10

S-3 filed Nov 12, 2026 at 19:49 ET

Alaunos Therapeutics filed an S-3 shelf registration statement to register 382,090,789 shares of common stock for resale by selling stockholders, primarily in connection with the October 2026 reverse merger with Velaris Therapeutics and a concurrent $350 million PIPE financing. The shares include those issuable upon conversion of Series B and Series C preferred stock issued to former Velaris stockholders and PIPE investors. The company will not receive any proceeds from the resale.

  • S-3 registers 382,090,789 shares for resale by selling stockholders, representing massive potential dilution relative to 4,208,359 shares outstanding as of November 11, 2026
  • Shares include 105,286,000 shares issuable upon conversion of Series B preferred (Velaris merger consideration), 33,054,000 Series C merger shares, 687,789 PIPE common shares, and 243,063,000 PIPE conversion shares
  • Conversion of preferred shares requires stockholder approval (Conversion Approval and Authorized Share Increase); beneficial ownership limitations of 4.99% to 19.99% apply per holder
  • Company will not receive any proceeds from the resale; proceeds go entirely to selling stockholders

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access